Home

ANTHONY E MAIDA III

CIK 1273213 · DIRECTOR AND CMO - TRANS. MED. · last filed 2026-07-14

ANTHONY E MAIDA III is a DIRECTOR AND CMO - TRANS. MED. who has filed 57 SEC Form 4 insider transactions across 4 companies since 2007. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. 49 SEC filings were submitted jointly with SPECTRUM PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

57

Lifetime Open-Market Net

-$1.52M

Filer Profile

Reported Address
157 TECHNOLOGY DR
IRVINE, CA 92618
Related Filers
SPECTRUM PHARMACEUTICALS INC — 49 joint filings, latest 2019-05-31
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
9 METERS BIOPHARMA, INC. (NMTR) Delisted Director — $0.07 — $0 1 2020-05-04
9 METERS BIOPHARMA, INC. (INNT) Delisted Director — — — $0 2 2019-06-04
SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Director 80,767 $1.03 $83.2K -$1.52M 39 2019-05-31
ONCOSEC MEDICAL Inc (ONCS) Delisted Director — $0.28 — $0 4 2017-04-03

Recent Filings

57 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-14 — Grant (A) — $0
2021-09-08 — Grant (A) — $0
2021-07-16 — Mixed +938,646 $0
2020-05-04 9 METERS BIOPHARMA, INC. (NMTR) Delisted Grant (A) — $0 EDGAR
2019-06-04 9 METERS BIOPHARMA, INC. (INNT) Delisted Grant (A) — $0 EDGAR
2019-05-31 SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Mixed +7,357 -$25.9K EDGAR
2019-05-13 — Grant (A) — $0
2019-04-12 SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Sell (S) −10,738 -$114.6K EDGAR
2019-03-22 SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Mixed — -$27.2K EDGAR
2019-02-22 SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted Mixed — -$36.2K EDGAR
Showing 1–10 of 57
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.